Ribomic Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Yoshikazu Nakamura

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	12.6yrs
CEO sahipliği	1.4%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	6.6yrs

Son yönetim güncellemeleri

Recent updates

Companies Like Ribomic (TSE:4591) Are In A Position To Invest In Growth

Oct 30

We're Not Very Worried About Ribomic's (TSE:4591) Cash Burn Rate

Jul 02

CEO

Yoshikazu Nakamura (77 yo)

12.6yrs

Görev süresi

Mr. Yoshikazu Nakamura, Ph.D. has been the President at Ribomic Inc. since April 2012 and has been its Chief Executive Officer since 2012. Mr. Nakamura has been a Representative Director at Ribomic Inc. Oc...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yoshikazu Nakamura	CEO, President & Representative Director	19.1yrs	Veri yok	1.4% ¥ 47.1m
Hisato Oiwa	Executive Officer	no data	Veri yok	Veri yok
Toshiaki Nishihata	Independent Outside Director	8.4yrs	Veri yok	Veri yok
Karl G. Csaky	Member of Scientific Advisory Board	6.8yrs	Veri yok	Veri yok
Yutaka Yabe	Outside Auditor	14.4yrs	Veri yok	Veri yok
Robert B. Bhisitkul	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Rajendra Apte	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Yasuhiro Fujii	Independent Outside Auditor	6.4yrs	Veri yok	Veri yok
Pavel Krejcí	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Masatsugu Nakamura	Member of Scientific Advisory Board	less than a year	Veri yok	Veri yok
Senya Matsufuji	Independent Outside Director	3.4yrs	Veri yok	0.098% ¥ 3.3m
Toshinobu Fujiwara	Independent Outside Director	1.4yrs	Veri yok	Veri yok

6.6yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 4591 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.6 yıldır).

Ribomic Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Ribomic Inc., Annual General Meeting, Jun 25, 2024

Ribomic Inc., Annual General Meeting, Jun 27, 2023

Less than half of directors are independent

Ribomic Inc., Annual General Meeting, Jun 28, 2022

Less than half of directors are independent

Recent updates

Companies Like Ribomic (TSE:4591) Are In A Position To Invest In Growth

Ribomic Inc. to Report Q2, 2025 Results on Nov 12, 2024

Ribomic Inc. Announces Completion of Patient Enrollment in Early Phase Ii Study of Umedaptanib Pegol for Achondroplasia and Initiation of Dosing in Cohort 2 of Early Phase Ii Clinical Study

We're Not Very Worried About Ribomic's (TSE:4591) Cash Burn Rate

Ribomic Inc. to Report Q1, 2025 Results on Aug 09, 2024

New minor risk - Shareholder dilution

Ribomic Inc., Annual General Meeting, Jun 25, 2024

New minor risk - Shareholder dilution

Ribomic Inc. to Report Fiscal Year 2024 Results on May 14, 2024

Ribomic Inc. announced that it has received ¥4.192212 million in funding from SMBC Nikko Securities Inc.

Ribomic Inc. announced that it expects to receive ¥4.192212 million in funding from SMBC Nikko Securities Inc.

Ribomic Inc. to Report Q3, 2024 Results on Feb 13, 2024

RIBOMIC Phase I and II Data Published in the Eye

First half 2024 earnings released

Ribomic Inc. to Report Q2, 2024 Results on Nov 13, 2023

New minor risk - Share price stability

First quarter 2024 earnings released

Ribomic Inc. to Report Q1, 2024 Results on Aug 10, 2023

Ribomic Inc., Annual General Meeting, Jun 27, 2023

Full year 2023 earnings released

Third quarter 2023 earnings released: JP¥18.86 loss per share (vs JP¥12.37 loss in 3Q 2022)

Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023

Ribomic Inc. to Report Q3, 2023 Results on Feb 10, 2023

Ribomic Inc. Announces the First Case Registration of Observational Study for RBM-007 Early Phase2 Development Project in Achondroplasia Patients

Second quarter 2023 earnings released: JP¥9.28 loss per share (vs JP¥15.44 loss in 2Q 2022)

Less than half of directors are independent

Second quarter 2023 earnings released: JP¥9.28 loss per share (vs JP¥15.44 loss in 2Q 2022)

Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023

Ribomic Inc. announced that it expects to receive ¥5.1372 million in funding

Ribomic Inc. to Report Q2, 2023 Results on Nov 11, 2022

First quarter 2023 earnings released: JP¥21.46 loss per share (vs JP¥12.04 loss in 1Q 2022)

RIBOMIC Announces Publication of anti-TGF-ß1 Aptamer Data Demonstrating Enhancement of anti-cancer Drug Efficacy

Ribomic Inc. to Report Q1, 2023 Results on Aug 09, 2022

Full year 2022 earnings released: JP¥59.92 loss per share (vs JP¥46.16 loss in FY 2021)

Ribomic Inc., Annual General Meeting, Jun 28, 2022

Less than half of directors are independent

Ribomic Inc. Announces Completion of IND submission for an Observational Study for Continuous Phase 2 Trial of RBM-007 for Treatment of Achondroplasia

Ribomic Inc. to Report Fiscal Year 2022 Results on May 13, 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Ribomic Inc. to Report Q3, 2022 Results on Feb 14, 2022

RIBOMIC Announces Preliminary Topline Data from Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration

Second quarter 2022 earnings released: JP¥15.44 loss per share (vs JP¥11.57 loss in 2Q 2021)

First quarter 2022 earnings released: JP¥12.04 loss per share (vs JP¥13.82 loss in 1Q 2021)

Ribomic Inc. Completes Patient Enrollment of Its US Phase 2 Clinical Trial of RBM-007 for Wet Age-Related Macular Degeneration (Tofu Study)

Ribomic Announces First Patient Dosed in an Investigator Sponsored Trial of RBM-007 in Treatment Naive Wet AMD Patients

Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2022

Ribomic Inc. Announces Completion of Its Phase I Trial of RBM-007 for the Treatment of Achondroplasia

Full year 2021 earnings released: JP¥46.16 loss per share (vs JP¥53.62 loss in FY 2020)

Third quarter 2021 earnings released: JP¥9.49 loss per share (vs JP¥15.71 loss in 3Q 2020)

Ribomic Inc. and ASKA Pharmaceutical Co., Ltd. Announces Execution of A Multi-Year Joint Research and Development Agreement for Drug Discovery Research and Development

Ribomic Inc. Announces Completion of 50% of Enrollment of its Phase 2 Clinical Trial for Wet Age-Related Macular Degeneration (Tofu Study)

New 90-day low: JP¥352

Ribomic Inc. to Report Q1, 2021 Results on Aug 07, 2020

CEO

Görev süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş